inFoods IBS Test Now Validated for Use with Simple Finger Stick Whole Blood Collection Technology - Seite 2

Mr. Robert Carlson, Biomerica’s Chief Commercial Officer stated, "This advancement reflects our continued commitment to innovation and significantly expands the number of physician offices that can use the inFoods IBS system to create treatment protocols for their IBS patients". "Our goal is to make living with IBS easier by providing a personalized and accessible test that empowers patients to understand potential food triggers and help control their condition."

The inFoods IBS clinical study was performed at several prominent centers including Mayo Clinic, Beth Israel Deaconess Medical Center Inc. - a Harvard Medical School Teaching Hospital, Houston Methodist Hospital, and the University of Michigan. In data presented May 8^th at the 2023 Digestive Disease Week (DDW) annual meeting, clinical results for improvement in the Abdominal Pain Intensity (API) responder endpoint of >30%, for IBS patients in the treatment diet arm had a statistically significant improvement over patients in the placebo diet arm (p-value of 0.0246). The improvement for patients in the treatment arm versus the placebo arm is considered clinically significant and is similar and, in some cases, better than the current drugs in the market.

About InFoods IBS:
The InFoods IBS test involves a simple blood collection procedure and is designed to assess a patient’s above normal immunoreactivity to specific foods. Instead of difficult to manage broad dietary restrictions, physicians can now use the InFoods IBS information to make targeted, patient-specific recommendations about specific foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea and constipation. Further information about Biomerica’s patented InFoods Technology Platform can be found at: https://biomerica.com/inFoods/our-technology/

About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point of care (in home and in physicians’ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company’s products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica’s primarily focus is on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.